Vaxart (VXRT) Releases Quarterly Earnings Results

Vaxart (NASDAQ:VXRT) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.92) EPS for the quarter, MarketWatch Earnings reports. The business had revenue of $0.28 million during the quarter. Vaxart had a negative return on equity of 195.55% and a negative net margin of 317.57%.

Shares of NASDAQ:VXRT traded down $0.34 during trading on Friday, hitting $2.64. The company’s stock had a trading volume of 183,719 shares, compared to its average volume of 99,802. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.90 and a current ratio of 2.90. Vaxart has a fifty-two week low of $2.37 and a fifty-two week high of $9.46.

COPYRIGHT VIOLATION NOTICE: This story was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2018/11/10/vaxart-vxrt-releases-quarterly-earnings-results.html.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines.

Featured Article: What does RSI mean?

Earnings History for Vaxart (NASDAQ:VXRT)

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit